Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 16/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 16/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.63 |
| ▸ | FAP | Q12884 | 11/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171016 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4108438 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL4159848 | 0.95 | DPP4 (0.59) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL4102171 | 0.95 | DPP4 (0.59) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8248410 | 0.92 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4167916 | 0.92 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4168303 | 0.92 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13803837 | 0.91 | DPP4 (0.54) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13804096 | 0.91 | DPP4 (0.51) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4168001 | 0.89 | DPP4 (0.60) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| WO-2006134613-A2 | NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149504-A1 | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.